Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2011 Dec 1;184(11):1234-6.
doi: 10.1164/rccm.201104-0697ED.

Con: the case for expanded lung cancer research support

Mark W Geraci, Robert L Keith
Editorial

Con: the case for expanded lung cancer research support

Mark W Geraci et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
U.S. cancer deaths versus federal research funding per death. Data for 2009 demonstrate that lung cancer has the lowest research funding per cancer death compared with next three deadliest cancers: colorectal, breast, and prostate. Reprinted by permission from Reference . Estimated deaths by cancer type in the U.S. for 2009 are from the American Cancer Society Facts and Figures, 2009: http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-figures-2009. Annual funding figures represent the National Cancer Institute (NCI) and Department of Defense estimated 2009 spending*: NCI:http://budgettool.cancer.gov/budget-spending/funding-by-cancer-type/fiscal-year-2009.aspx. Department of Defense Lung, Breast, and Prostate Research Program descriptions available at http://cdmrp.army.mil./researchprograms.Wshtml. * While the Centers for Disease Control & Prevention (CDC) also funds cancer research, a breakdown of spending between research and public health interventions is not currently available.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin 2009;59:225–249 - PubMed
    1. Slatore CG, Au DH, Gould MK. An Official American Thoracic Society Systematic Review: Insurance status and disparities in lung cancer practices and outcomes. Am J Respir Crit Care Med 2010;182:1195–1205 - PubMed
    1. Onega T, Duell EJ, Shi X, Demidenko E, Gottlieb D, Goodman DC. Influence of NCI Cancer Center attendance on mortality in lung, breast, colorectal, and prostate cancer patients. Med Care Res Rev 2009;66:542–560 - PMC - PubMed
    1. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031–1037 - PubMed
    1. Sawyers CL. Even better kinase inhibitors for chronic myeloid leukemia. N Engl J Med 2010;362:2314–2315 - PubMed

Publication types

MeSH terms

Substances